Pfizer
Pfizer Makes $15M Equity Investment in Cardiff Oncology
The equity investment will help advance Cardiff's development of onvansertib and grants Pfizer rights of first access to data from its development programs.
Imugene to Begin Phase II Trial of B-Cell Immunotherapy in HER2-Postive Gastric Cancer
The trial will evaluate Imugene's HER-Vaxx plus Merck KGaA and Pfizer's Bavencio and chemo in patients with HER2-positive gastric cancers.
Pfizer Q3 Oncology Revenues Jump 12 Percent
Sales of Pfizer's Ibrance and Lorbrena grew internationally year over year, while its BRAF and MEK inhibitors reported double-digit growth in the US.
Erasca Begins Phase Ib/II Master Protocol Trial of ERAS-007 in Gastrointestinal Cancers
The company will initially study the ERK1/2 inhibitor in combination with other therapies in biomarker-defined advanced colorectal cancers.
Cedars-Sinai Researchers Hunt for Rx Options for RAF-Mutated Pancreatic Cancer in Real-World Data
Premium
After a retrospective analysis identified targeted treatment opportunities for this subset of patients, researchers began a Phase II trial of a MEK and BRAF inhibitor.
Jul 28, 2021
Pfizer Nearly Doubles Q2 Revenues
Mar 30, 2021